Evidence mapPaperPMID 42365207Full record

ArticleBiogerontology2026

A multi-ingredient food supplement slows age-dependent decline of mobility and influences gene expression in C. elegans.

Chad Yanyatan, Karthik Mohanraj, Michael Fasseas, Sushmita Maitra, Ed Van Harmelen, Chris Saunter, David Weinkove

Abstract read
In one paragraph

Article in Biogerontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chad YanyatanMagnitude Biosciences Ltd., NETPark Plexus, Thomas Wright Way, Sedgefield, TS21 3FD, UK.
Karthik MohanrajMagnitude Biosciences Ltd., NETPark Plexus, Thomas Wright Way, Sedgefield, TS21 3FD, UK.
Michael FasseasMagnitude Biosciences Ltd., NETPark Plexus, Thomas Wright Way, Sedgefield, TS21 3FD, UK.
Sushmita MaitraMagnitude Biosciences Ltd., NETPark Plexus, Thomas Wright Way, Sedgefield, TS21 3FD, UK.
Ed Van HarmelenYouth and Earth, Huckletree West-Mediaworks, 191 Wood Lane, London, W12 7FP, UK.
Chris SaunterMagnitude Biosciences Ltd., NETPark Plexus, Thomas Wright Way, Sedgefield, TS21 3FD, UK.
David WeinkoveMagnitude Biosciences Ltd., NETPark Plexus, Thomas Wright Way, Sedgefield, TS21 3FD, UK. david.weinkove@durham.ac.uk.ORCID https://orcid.org/0000-0001-7399-1202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of developing interventions to slow ageing is not only lifespan extension but more importantly to increase healthspan, the period of life spent in active good health. Nutritional interventions have emerged as a potential strategy to maintain health with age. Testing these interventions for effects on human ageing would take several years and require large cohort sizes. We therefore employed C. elegans as a rapidly ageing model organism to investigate the effects of two commercially available nutrition-based products on ageing-related decline of mobility as an indication of healthspan. These products are multi-ingredient formulations comprising vitamins, minerals, antioxidants, amino acids and botanical extracts. They include compounds expected to positively influence ageing such as Dihydronicotinamide mononucleotide, NAD + booster, trans-resveratrol, taurine, pterostilbene and bioflavonoids. V14™ contains 40 + ingredients and AG1® contains 70 + ingredients with 5 additional probiotic strains. Mobility-based readouts over time were obtained using WormGazer™ imaging technology. Worms exposed to V14™ showed increased movement and speed with age compared to those exposed to AG1® and to a solvent control. To investigate the underlying mechanisms, transcriptomic profiling was performed on V14™ exposed worms, revealing modulation of pathways involved in metabolism and stress responses, processes associated with ageing. Collectively, these findings suggest that V14™ delays age-related decline in C. elegans and highlight the potential of targeted nutritional interventions to modulate pathways relevant to human ageing.

Indexed as

AgingCaenorhabditis elegansDietary SupplementsAnimalsAntioxidantsGene Expression RegulationLongevityAntioxidantsAgeingCaenorhabditisdietary supplementationeleganshealthspanmobility declinetranscriptomics

Identifiers

PMID42365207
PMCPMC13310222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.